Sino-Singapore Health: Innovative drug for the treatment of gastrointestinal and pancreatic neuroendocrine tumors has been approved to begin Phase III clinical research. ITM-11 is an innovative RDC drug based on radionuclide coupling technology for the targeted killing and treatment of gastroenteropancreatic neuro endocrine tumors (GEP-NETs) This study plans to enroll at least 202 patients in more than ten countries around the world.
Efficacy, safety, and patient-reported outcomes in patients with grade 2 and 3, somatostatin receptor-positive (SSTR+) GEP- NETs.